title: The standardization of nonsterile compounding: a study in quality control and assessment for hormone compounding.
abstract: Sterile and nonsterile compounding of medication has attracted much attention over the last few years due to the onset of various infections and negative compounding practices. This paper reports on the standardization of compounded hormones utilizing the Wiley Protocol, which provides nonsynthetic bioidentical estradiol, progesterone, dehydroepiandrosterone, and testosterone in a transdermal topical cream base for women and men in a standardized dosing regimen. Here, we present data from 2008 through 2012, which details the process of standardization and quality testing of the hormones through submission of random compounded samples for quality control and assessment. Pharmacies delivering the Wiley Protocol were required to follow the same compounding formulation, as well as submit random samples for quarterly testing. Sample concentrations were tested using high-performance liquid chromatography. We found that pharmacies that submitted samples had a 91% passing rating with a percent of target of 98.6% +/- 8.4%. It was also determined that pharmacies that prepared more compounded cream had a higher passing rating than those that prepared limited quantities. We found that standardization across multiple pharmacies could be achieved through quarterly testing of submitted samples by a third-party laboratory when following necessary procedures as defined by the Wiley Protocol. It was also determined that experience and training were a critical factor in the mixing of compounded prescriptions, with high consistency and accuracy providing patient safety.
authors.forename: T S
authors.initials: TS
authors.lastname: Wiley
authors.forename: R D
authors.initials: RD
authors.lastname: Odegard
authors.forename: J
authors.initials: J
authors.lastname: Raden
authors.forename: J T
authors.initials: JT
authors.lastname: Haraldsen
mesh_terms: D000279:Administration, Cutaneous; D059451:Biosimilar Pharmaceuticals / Q000008:administration & dosage / Q000737:chemistry / Q000592:standards*; D002626:Chemistry, Pharmaceutical / Q000592:standards*; D003687:Dehydroepiandrosterone / Q000592:standards; D004339:Drug Compounding / Q000592:standards*; D004958:Estradiol / Q000592:standards; D005260:Female; D012739:Gonadal Steroid Hormones / Q000008:administration & dosage / Q000737:chemistry / Q000592:standards*; D019983:Guideline Adherence; D020249:Hormone Replacement Therapy / Q000592:standards*; D006801:Humans; D008297:Male; D009824:Ointments; D061214:Patient Safety; D017410:Practice Guidelines as Topic; D011374:Progesterone / Q000592:standards; D011786:Quality Control; D012015:Reference Standards; D015203:Reproducibility of Results; D013739:Testosterone / Q000592:standards; D013997:Time Factors
chemical_list: D059451:Biosimilar Pharmaceuticals; D012739:Gonadal Steroid Hormones; D009824:Ointments; D013739:Testosterone; D003687:Dehydroepiandrosterone; D011374:Progesterone; D004958:Estradiol